



GYNECOLOGIC CANCERS

Integrating Brachytherapy and Emerging Systemic Therapies into Cervical Cancer Care

Presented by: Junzo P. Chino, MD, *Duke Cancer Institute*

Overview: Although brachytherapy remains a critical component in the definitive management of cervical cancer, it continues to be underutilized in the United States due to barriers such as limited training opportunities and financial constraints. At the same time, advances in systemic therapy are reshaping the treatment landscape. With the recent FDA approval of tisotumab vedotin-tftv for patients with recurrent or metastatic cervical cancer progressing after chemotherapy, it is equally important to stay informed about emerging antibody–drug conjugates and other novel agents currently in development.

Learning Objectives:

- Emphasize the importance of brachytherapy in the management of cervical cancer, address factors contributing to its underutilization, and explore strategies to mitigate them.
- Review new systemic therapy options for recurrent and metastatic cervical cancer, with a focus on recent FDA approvals and emerging agents in the pipeline.

Applying Molecular Advances in the Management of Endometrial Cancer

Presented by: Ritu Salani, MD, MBA, *UCLA Jonsson Comprehensive Cancer Center*

Overview: Endometrial cancer is increasingly classified by molecular subtypes and biomarkers that impact prognosis and treatment. Treatment paradigms are impacted by molecular classification, and ongoing clinical trials are biomarker-driven. Molecular testing has become the foundation of personalized endometrial cancer treatment. This session highlights the evolving molecular landscape of endometrial cancer to guide optimal treatment selection and de-escalate adjuvant treatment strategies.

Learning Objectives:

- Describe the evolving molecular landscape in endometrial cancer.
- Review new molecularly driven targeted therapy options and de-escalating adjuvant therapy strategies for endometrial cancer.

Evolving Ovarian Cancer Care: Surgical and Systemic Approaches

Presented by: Shitanshu Uppal, MBBS, MBA, *University of Michigan Rogel Cancer Center*

Overview: The treatment landscape for recurrent ovarian, fallopian tube, and primary peritoneal cancers has significantly evolved due to new FDA approvals and emerging clinical data. Targeted therapies are now considered an important component of care for patients with recurrent disease. The NCCN Guidelines® for Ovarian Cancer have been updated to reflect this new information and will continue to be revised based on the changing treatment landscape.

Learning Objectives:

- Recognize current options for surgical management of ovarian, fallopian tube, and primary peritoneal cancers.
- Identify systemic therapy options, including targeted agents, for patients with advanced ovarian, fallopian tube, and primary peritoneal cancers.